Raghuram Selvaraju

Thomas Flaten

Nazibur Rahman

James Sidoti

Naz Rahman

- **Brendan O'Grady** separated from his role as Chief Executive Officer and director of Assertio Holdings, Inc. effective **October 27, 2025**.  **[1808665_0001104659-25-104439_tm2529606d1_8k.htm:1]** 
- **Mark Reisenauer**, a current board member, was appointed as the new Chief Executive Officer, effective immediately upon Mr. O'Grady's separation.  **[1808665_0001104659-25-104439_tm2529606d1_8k.htm:1]** **[1808665_0001104659-25-104439_tm2529606d1_ex99-1.htm:1]** 
- Mr. Reisenauer's compensation package includes an annual base salary of **$800,000**, an annual target cash bonus opportunity of **85% of his base salary**, a stock option award for **1,000,000 shares**, and **500,000 restricted stock units**, with equity awards vesting over three years.  **[1808665_0001104659-25-104439_tm2529606d1_8k.htm:1]** 
- Assertio plans to release its third-quarter 2025 financial results on **November 10, 2025**, and expects to update guidance within the current range at that time.  **[1808665_0001104659-25-104439_tm2529606d1_ex99-1.htm:1]**

Assertio Holdings, Inc. Announces CEO Transition and New Executive Compensation

- Assertio Holdings, Inc.'s subsidiary, Spectrum Pharmaceuticals, Inc., entered into an **amendment and restatement of its supply agreement** with Hanmi Pharmaceutical Co. Ltd. for **ROLVEDON drug substance** on **October 7, 2025**.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]** 
- The amendment establishes **long-term pricing** for ROLVEDON, including a **mid-single digit percentage reduction** to the price Spectrum previously agreed to pay.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]** 
- The new price is **fixed throughout the remaining term** of Spectrum's license agreement, subject to potential price increases from **January 1, 2028**, if the supplier's costs exceed a set threshold, and potential reductions if global market volume for ROLVEDON exceeds a specified threshold.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]** 
- Spectrum is required to provide an **annual forecasted purchase plan**, with **at least fifty percent** of any included orders designated as binding, though there are no minimum purchase requirements.  **[1808665_0001104659-25-098758_tm2528497d1_8k.htm:1]**

Assertio Holdings (ASRT)